Deciphering the role of IGFBP5 in delaying fibrosis and sarcopenia in aging skeletal muscle: therapeutic implications and molecular mechanisms DOI Creative Commons
Luze Shi,

Zheci Ding,

Jiwu Chen

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 12, 2025

Introduction Sarcopenia is a condition characterized by the loss of muscle fibers and excessive deposition extracellular matrix proteins. The interplay between atrophy fibrosis central feature sarcopenia. While mechanisms underlying skeletal aging remain incompletely understood, cellular senescence has emerged as key contributor. This study investigates role D-galactose (D-gal) in inducing fibroblasts fibrosis, aims to find regulator process serve therapeutical target. Methods To discover D-gal markers expression fibrosis-related proteins were assessed after introducing among fibroblasts, strength mass. severity also verified using H&E staining Masson trichrome treatment via subcutaneous injection mice. Subsequently, mRNA sequencing (RNA-seq) was performed differential expressed genes identified under or control treatment, D-GAL-driven fibrosis. IGFBP5 then validated D-GAL treated IGFBP5-knockdown vitro analyzing level markers. And results further confirmed vivo SAMP8 mice with histological examinations. Results effectively induced well atrophy, mass function RNA-seq. validation tests showed that could alleviate D-GAL-induced fibroblast Discussion emerging findings provide new insights into molecular age-related highlight potential therapeutic Further research needed validate these explore related clinical applications.

Язык: Английский

Deciphering the role of IGFBP5 in delaying fibrosis and sarcopenia in aging skeletal muscle: therapeutic implications and molecular mechanisms DOI Creative Commons
Luze Shi,

Zheci Ding,

Jiwu Chen

и другие.

Frontiers in Pharmacology, Год журнала: 2025, Номер 16

Опубликована: Март 12, 2025

Introduction Sarcopenia is a condition characterized by the loss of muscle fibers and excessive deposition extracellular matrix proteins. The interplay between atrophy fibrosis central feature sarcopenia. While mechanisms underlying skeletal aging remain incompletely understood, cellular senescence has emerged as key contributor. This study investigates role D-galactose (D-gal) in inducing fibroblasts fibrosis, aims to find regulator process serve therapeutical target. Methods To discover D-gal markers expression fibrosis-related proteins were assessed after introducing among fibroblasts, strength mass. severity also verified using H&E staining Masson trichrome treatment via subcutaneous injection mice. Subsequently, mRNA sequencing (RNA-seq) was performed differential expressed genes identified under or control treatment, D-GAL-driven fibrosis. IGFBP5 then validated D-GAL treated IGFBP5-knockdown vitro analyzing level markers. And results further confirmed vivo SAMP8 mice with histological examinations. Results effectively induced well atrophy, mass function RNA-seq. validation tests showed that could alleviate D-GAL-induced fibroblast Discussion emerging findings provide new insights into molecular age-related highlight potential therapeutic Further research needed validate these explore related clinical applications.

Язык: Английский

Процитировано

0